Press coverage about Sarepta Therapeutics (NASDAQ:SRPT) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sarepta Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.9397794979975 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- First Duchenne Muscular Dystrophy Patient Dosed in Systemic Microdystrophin Gene Therapy (prnewswire.com)
- Your Today’s Wake-Up Call: Sarepta Therapeutics, Inc. (SRPT), Genesis Healthcare, Inc. (GEN) – Market Movers (financialqz.com)
- Clue to Identify In Play Stocks (Relative Volume) – Sarepta Therapeutics Inc (NASDAQ: SRPT) – Alpha Beta Stock (alphabetastock.com)
- Hot Tickers: Sarepta Therapeutics, Inc. (SRPT), Ross Stores, Inc. (ROST) – Market Movers (financialqz.com)
- Stocks Trend Prediction: Sarepta Therapeutics, Inc. (SRPT), Ross Stores, Inc. (ROST) – Market Movers (financialqz.com)
SRPT has been the topic of a number of research analyst reports. Goldman Sachs Group reissued a “buy” rating and set a $71.00 price objective on shares of Sarepta Therapeutics in a report on Friday, October 6th. ValuEngine cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 3rd. They set a “buy” rating and a $75.00 price objective on the stock. Oppenheimer reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. Finally, BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, December 25th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and eighteen have issued a buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $63.88.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The firm had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. During the same period last year, the firm posted ($0.95) EPS. equities analysts anticipate that Sarepta Therapeutics will post -3.07 earnings per share for the current year.
In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now directly owns 13,333 shares in the company, valued at approximately $745,181.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Shamim Ruff sold 10,000 shares of Sarepta Therapeutics stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the transaction, the senior vice president now owns 37,045 shares in the company, valued at $2,037,475. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.